Furthermore, due to SERT expression in platelets and megakaryocytes and again due to mIBG lacking NET selectivity, mIBG therapy in neuroendocrine cancer is often limited by myelosuppression with low platelet counts [77]. This evidence concerns the gene SLC6A2 and neuroendocrine carcinoma.